In vitro experiments showed that combined treatment (ZD55-SATB1 plus DTX) had the highest efficacy to inhibit the viability, invasion and migration of prostate cancer cells while had no significant effect on the viability of normal prostate cells. Here, SATB1 is linked to prostate carcinoma.